Page last updated: 2024-11-13
butobendin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
butobendin: RN refers to (S-(R*,R*))-isomer; Craviten is tradename; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Comparison of the decline of the same absolute and relative serum concentrations of the drug and the variation of pharmacokinetic parameters with the dose leads to the conclusion, that the elimination of Craviten in rats cannot be described by first-order kinetics." | ( Pharmacokinetic investigations of Craviten. II. Dose-dependent elimination kinetics in rats following rapid intravenous injection. Danek, A; Witek, J, ) | 0.13 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " To increase bioavailability in men the tablets or enteric coated tablets should be made according to the results of clinical trials." | ( In vitro study of (2S, 2'S) N,N'-dimethyl-N, N'-bis [1(3', 4', 5'-trimethoxybenzoyloxy) butyl-2] ethylenediamine salts and their bioavailability. Bartkowicz, S; Kluczykowska, B; Krówczyński, L; Stozek, T; Wajdowicz, A, ) | 0.13 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to improve the oral dosage form of the title compound." | ( In vitro study of (2S, 2'S) N,N'-dimethyl-N, N'-bis [1(3', 4', 5'-trimethoxybenzoyloxy) butyl-2] ethylenediamine salts and their bioavailability. Bartkowicz, S; Kluczykowska, B; Krówczyński, L; Stozek, T; Wajdowicz, A, ) | 0.13 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (7.14%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (3.57%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 25 (89.29%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||